AI assistant
Sending…
Ernexa Therapeutics Inc. — Director's Dealing 2021
Jun 30, 2021
35259_dirs_2021-06-30_942ee8ec-759c-4d14-a3ce-c7ef8a07fea4.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Brooklyn ImmunoTherapeutics, Inc. (BTX)
CIK: 0000748592
Period of Report: 2021-06-28
Reporting Person: DAmour Kevin (N/A)
More from Ernexa Therapeutics Inc.
Major Shareholding Notification
2026
May 14
Annual Report
2026
May 11
Proxy Solicitation & Information Statement
2026
May 11
Proxy Solicitation & Information Statement
2026
May 11
Interim / Quarterly Report
2026
May 11
Share Issue/Capital Change
2026
May 4
Regulatory Filings
2026
Apr 13
Regulatory Filings
2026
Apr 1
Regulatory Filings
2026
Mar 31
Capital/Financing Update
2026
Mar 24